Calley Means is co-piloting Kennedy’s overhaul of HHS and he makes no apologies for sweeping cuts to agency's bureaucracy.

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

Ex-vaccine regulator Peter Marks promoted "ineffective therapy that gave patients false hope, eroded trust in the regulatory ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Shares of early-stage biotech stocks, including Biohaven ( BHVN -6.50%), Recursion Pharmaceuticals ( RXRX -7.37%), and CRISPR ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, ...

Learn more about whether Corcept Therapeutics Incorporated or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial ...